Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens
- PMID: 8011298
- DOI: 10.1146/annurev.iy.12.040194.004113
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens
Abstract
Oral tolerance is a long recognized method to induce peripheral immune tolerance. The primary mechanisms by which orally administered antigen induces tolerance are via the generation of active suppression or clonal anergy. Low doses of orally administered antigen favor active suppression whereas higher doses favor clonal anergy. The regulatory cells that mediate active suppression act via the secretion of suppressive cytokines such as TGF beta and IL-4 after being triggered by the oral tolerogen. Furthermore, antigen that stimulates the gut-associated lymphoid tissue preferentially generates a Th2 type response. Because the regulatory cells generated following oral tolerization are triggered in an antigen-specific fashion but suppress in an antigen nonspecific fashion, they mediate "bystander suppression" when they encounter the fed autoantigen at the target organ. Thus it may not be necessary to identify the target autoantigen to suppress an organ-specific autoimmune disease via oral tolerance; it is necessary only to administer orally a protein capable of inducing regulatory cells that secrete suppressive cytokines. Orally administered autoantigens suppress several experimental autoimmune models in a disease- and antigen-specific fashion; the diseases include experimental autoimmune encephalomyelitis (EAE), uveitis, and myasthenia, collagen- and adjuvant-induced arthritis, and diabetes in the NOD mouse. In addition, orally administered alloantigen suppresses alloreactivity and prolongs graft survival. Initial clinical trials of oral tolerance in multiple sclerosis, rheumatoid arthritis, and uveitis have demonstrated positive clinical effects with no apparent toxicity and decreases in T cell autoreactivity.
Similar articles
-
Oral tolerance: therapeutic implications for autoimmune diseases.Clin Dev Immunol. 2006 Jun-Dec;13(2-4):143-57. doi: 10.1080/17402520600876804. Clin Dev Immunol. 2006. PMID: 17162357 Free PMC article. Review.
-
Oral tolerance for the treatment of autoimmune diseases.Annu Rev Med. 1997;48:341-51. doi: 10.1146/annurev.med.48.1.341. Annu Rev Med. 1997. PMID: 9046967 Review.
-
Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases.Biopolymers. 1997;43(4):323-35. doi: 10.1002/(SICI)1097-0282(1997)43:4<323::AID-BIP5>3.0.CO;2-X. Biopolymers. 1997. PMID: 9316395 Review.
-
Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse.Eur J Immunol. 1994 Sep;24(9):2104-9. doi: 10.1002/eji.1830240926. Eur J Immunol. 1994. PMID: 7522160
-
Immunomodulation of experimental autoimmune diseases via oral tolerance.Crit Rev Immunol. 2000;20(1):1-16. Crit Rev Immunol. 2000. PMID: 10770268 Review.
Cited by
-
Immune modulating peptides for the treatment and suppression of multiple sclerosis.Clin Immunol. 2012 Aug;144(2):127-38. doi: 10.1016/j.clim.2012.05.010. Epub 2012 Jun 5. Clin Immunol. 2012. PMID: 22722227 Free PMC article. Review.
-
Autoantibodies to αS1-casein are induced by breast-feeding.PLoS One. 2012;7(4):e32716. doi: 10.1371/journal.pone.0032716. Epub 2012 Apr 4. PLoS One. 2012. PMID: 22496735 Free PMC article.
-
Past, present, and future technologies for oral delivery of therapeutic proteins.J Pharm Sci. 2008 Jul;97(7):2497-523. doi: 10.1002/jps.21183. J Pharm Sci. 2008. PMID: 17918721 Free PMC article. Review.
-
Immunology and homeopathy. 3. Experimental studies on animal models.Evid Based Complement Alternat Med. 2006 Jun;3(2):171-86. doi: 10.1093/ecam/nel016. Epub 2006 May 2. Evid Based Complement Alternat Med. 2006. PMID: 16786046 Free PMC article.
-
Antiproliferative effects of homogenates derived from five strains of candidate probiotic bacteria.Appl Environ Microbiol. 1999 Nov;65(11):4725-8. doi: 10.1128/AEM.65.11.4725-4728.1999. Appl Environ Microbiol. 1999. PMID: 10543777 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical